Table 2.
Clinical studies of NPs for infectious and inflammatory diseases
| Role | Conditions | Interventions | Type | Primary outcome measures | Phases | Sponsor | NCT Number | Ref |
|---|---|---|---|---|---|---|---|---|
| Infectious diseases | ||||||||
| Vaccine | Coronavirus; COVID-19 | PepGNP-COVID19 | Peptide vaccine | SAEs; AESI | Phase1; Phase2 | Emergex Vaccines Holding Ltd. | NCT05633446 | |
| COVID-19 | mRNA-1273 | LNP mRNA vaccine | AEs; SAEs; MAAEs; AESIs; GMT; GMFR | Phase1; Phase2 | NIAID | NCT04889209 | ||
| COVID-19 | mRNA-1273 | LNP mRNA vaccine | MAAEs; NOCMCs); SAEs | Phase1 | NIAID | NCT04283461 | 761 | |
| COVID-19 | mRNA-1273.351 | LNP mRNA vaccine | MAAEs; NOCMCs; AESIs; SAEs; AEs | Phase1 | NIAID | NCT04785144 | ||
| COVID-19 | mRNA-1273 | LNP mRNA vaccine | Incidence; mean peak nasal viral load | Phase3 | NIAID | NCT04811664 | 762,763 | |
| COVID-19; HIV | mRNA-1273 | LNP mRNA vaccine | NAAT; ARDS | Phase2; Phase3 | COVID-19 Prevention Network | NCT05168813 | ||
| COVID-19 | HDT-301 | LNP repRNA vaccine | AEs; AESI; SAE; NOCMCs | Phase1 | HDT Bio | NCT05132907 | ||
| COVID-19 | HDT-301 | LNP repRNA vaccine | AEs; SAEs; AESI | Phase1 | SENAI CIMATEC | NCT04844268 | ||
| COVID-19 | BNT162b2 | LNP mRNA vaccine | GMTs; GMR; AEs; SAEs | Phase3 | BioNTech SE | NCT04816669 | ||
| COVID 19 | BNT162b2 | LNP mRNA vaccine | GMT; PRNT | Phase4 | The University of Hong Kong | NCT05057182 | 764 | |
| COVID-19 | PTX-COVID-19-B; Vaxzevria® | LNP mRNA vaccine | Immunogenicity response | Phase3 | Everest Medicines (Singapore) Pte., Ltd. | NCT05534035 | 765 | |
| COVID-19 | PTX-COVID-19-B | LNP mRNA vaccine | NT50; PBNA; AEs; SAEs; MAAEs; AESI; PIMMC | Phase3 | Everest Medicines (Singapore) Pte., Ltd. | NCT05534048 | ||
| COVID-19 | RNA MCTI CIMATEC HDT Vaccine | LNP; repRNA Vaccine | Ieutralizing antibody titers | Phase2 | Azidus Brasil | NCT05542693 | 766,767 | |
| COVID-19 | QTP104 | LNP repRNA vaccine | AEs; SAEs; AESI | Phase1 | Quratis Inc. | NCT05876364 | ||
| COVID-19 | AS03; BNT162b2; CoV2 preS dTM [B.1.351]; mRNA-1273 | LNP mRNA vaccine | GMFR; MSD; GMT | Phase1; Phase2 | NIAID | NCT05289037 | 768 | |
| COVID-19 | DS-5670a DAICHIRONA | LNP mRNA vaccine | AEs; GMT; GMFR | Phase1; Phase2 | Daiichi Sankyo Co. Ltd. | NCT04821674 | ||
| COVID-19 | ChulaCov19 vaccine | LNP mRNA vaccine | AEs; SAEs; GMT | Phase1; Phase2 | Chulalongkorn University | NCT04566276 | ||
| COVID-19 | Bivalent Moderna; Novavax | mRNA Vaccine; self-assembled protein NPs | IgG antibodies; solicited reactions | Phase3 | Murdoch Childrens Research Institute | NCT05658523 | ||
| COVID-19 | SARS-CoV-2 mRNA Vaccine | mRNA Vaccine | Primary efficacy endpoint | Phase3 | Walvax Biotechnology Co., Ltd. | NCT04847102 | ||
| COVID-19 | CoronaVac; Comirnaty | Inactivated vaccine; mRNA vaccine | GMT; PRNT | Phase4 | The University of Hong Kong | NCT05057169 | ||
| COVID-19 | SPFN_1B-06-PL; ALFQ | Ferritin-nanoparticle; LNP | Post-vaccination reactions | Phase1 | U.S. Army Medical Research and Development Command | NCT04784767 | 769,770 | |
| COVID-19 | COVID-19 rS | Self-assembled protein NPs | AEs; SAEs; MAAEs; AESIs; GMT; GMFR | Phase1; Phase2 | Novavax | NCT04368988 | ||
| COVID-19 | ChAdV68-S; SAM-LNP-S | Self-assembled protein NPs | AESIs; PIMMCs; MAAEs; NOCMCs | Phase1 | NIAID | NCT04776317 | 771 | |
| COVID-19 | GBP510&AS03 | Self-assembled protein NPs | AEs; SAEs; MAAEs; AESIs; GMFR | Phase1; Phase2 | SK Bioscience Co., Ltd. | NCT04750343 | 772 | |
| COVID-19 | GBP510 | Self-assembled protein NPs | AEs; SAEs; MAAEs; AESIs; GMT; GMFR | Phase1; Phase2 | SK Bioscience Co., Ltd. | NCT04742738 | 220 | |
| COVID-19 | ICC Vaccine | Self-assembled protein NPs | systemic AEs; MAAEs; AESIs; PIMMCs; SAEs | Phase1; Phase2 | Novavax | NCT04961541 | 773 | |
| COVID-19 | GBP510 | Self-assembled protein NPs | GMT; GMFR | Phase2 | Korea University Guro Hospital | NCT05175950 | ||
| COVID-19 | SARS-CoV-2 subunit protein recombinant vaccine | Self-assembled protein NPs | GMT | Phase2 | PT Bio Farma | NCT05525208 | ||
| COVID-19 | CIC Vaccine | Self-assembled protein NPs | AEs; MAAEs; AESIs; SAEs | Phase2 | Novavax | NCT05519839 | 774 | |
| COVID-19 | NVX-CoV2373 | Self-assembled protein NPs | AEs; SCR; GMT | Phase2 | Novavax | NCT05112848 | ||
| COVID-19 | SARS-CoV-2 rS/Matrix-M1 Adjuvant | Self-assembled protein NPs | (+) PCR-confirmed; AEs; MAAEs; MedDRA; GMTs; GMFRs | Phase2 | Novavax | NCT04533399 | ||
| COVID-19 | NVX-CoV2373; NVX-CoV2601 Bivalent BA.4/5 | Self-assembled protein NPs | GMTR; SRRs; NI | Phase2; Phase3 | Novavax | NCT05925127 | ||
| COVID-19 | COVID-19 vaccines | Self-assembled protein NPs | IgG antibodies | Phase3 | Murdoch Childrens Research Institute | NCT05387317 | ||
| COVID-19 | NVX-CoV2373; BBIBP-CorV vaccine | Self-assembled protein NPs | Utilizing ratio of IgG GMTs; MAAEs; AESIs; SAEs | Phase3 | Cogna Technology Solutions LLC | NCT05249816 | ||
| COVID-19 | COVID-19 Protein Subunit Recombinant Vaccine | Self-assembled protein NPs | GMT; seroconversion rate | Phase3 | PT Bio Farma | NCT05433285 | ||
| COVID-19 | Tozinameran; Elasomeran; Bivalent Pfizer; Bivalent Moderna | Self-assembled protein NPs | IgG antibodies | Phase3 | Murdoch Childrens Research Institute | NCT05543356 | ||
| COVID-19 | SARS-CoV-2 rS/Matrix M1-Adjuvant | Self-assembled protein NPs | Participants with symptomatic mild; moderate; or COVID-19 | Phase3 | Novavax | NCT04583995 | 775 | |
| COVID-19 | GBP510 adjuvanted with AS03 | Self-assembled protein NPs | GMTs | Phase3 | SK Bioscience Co., Ltd. | NCT05007951 | 776 | |
| COVID-19 | GBP510 adjuvanted with AS03 | Self-assembled protein NPs | GMFR | Phase3 | SK Bioscience Co., Ltd. | NCT05501522 | ||
| COVID-19 | NVX-CoV2515; NVX-Cov2373; NVX-CoV2540 | Self-assembled protein NPs | MN50; GMTs; SRRs; NAb | Phase3 | Novavax | NCT05372588 | ||
| COVID-19 | SARS-CoV-2 rS/Matrix-M1 Adjuvant (NVX-CoV2373) | Self-assembled protein NPs | Symptomatic; (+) PCR; MAAEs | Phase3 | Novavax | NCT04611802 | 207 | |
| COVID-19; HIV | Ad26.COV2. S Vaccine; SARS-CoV-2 rS; BNT162b2 | Self-assembled protein NPs | humoral immune responses | Phase2 | The Aurum Institute NPC | NCT05515042 | ||
| Influenza | H3 mRNA / LNP | LNP mRNA vaccine | AEs; CRF; SAEs; AESIs; HAI-Ab; GMTs | Phase1 | Sanofi Pasteur; a Sanofi Company | NCT05829356 | ||
| Influenza | DCVC H1 HA mRNA vaccine | LNP mRNA vaccine | AESIs; ILI; MAAEs; NOCMCs; SAEs; AEs | Phase1 | NIAID | NCT05945485 | ||
| Influenza | VRC H1ssF 3928 | LNP mRNA vaccine | AESIs; NOCMCs; SAEs; MAAEs; AEs | Phase1 | NIAID | NCT05755620 | ||
| Influenza | UFluA | Hemagglutinin stabilized stem nanoparticle vaccine | AEs; SAEs; AESIs; MAAEs | Phase1 | Emergent BioSolutions | NCT05155319 | 777 | |
| Influenza | Tri-NIV with NanoFlu | Self-assembled protein NPs | AEs; MAAEs; SAEs; SNMCs; MAE; SAE; HAI; GMR | Phase1; Phase2 | Novavax | NCT03293498 | ||
| Influenza | Quad-NIV | Self-assembled protein NPs | AEs; MAEs; SAEs; SNMCs; GMT | Phase2 | Novavax | NCT03658629 | ||
| Influenza | Quad-NIV with NanoFlu | Self-assembled protein NPs | GMFR; SCR; AEs; MAAEs; SAE; SNMCs | Phase3 | Novavax | NCT04120194 | 212 | |
| RSV | RSV mRNA LNP CL-0059&0137 | LNP RSV mRNA Vaccine | AEs; MAAEs; SAEs; AESIs; GMTs | Sanofi Pasteur; a Sanofi Company | Phase1; Phase2 | NCT05639894 | ||
| RSV; older adults | RSV-F Vaccine | Protein NPs | AEs; GMR; SCR; SRR | Novavax | Phase1 | NCT01709019 | ||
| RSV; Healthy volunteers | RSV-F Vaccine | Protein NPs | AEs; MAEs; SAEs; SNMCs; GMEU; GMR; SRR | Novavax | Phase1 | NCT02296463 | ||
| RSV | RSV-F Vaccine | Protein NPs | GMT; GMR; SCR; AEs | Novavax | Phase2 | NCT01704365 | ||
| RSV | RSV-F Vaccine | Protein NPs | GMEU; GMR; SRR; SCR2 and SCR4 | Novavax | Phase2 | NCT02593071 | ||
| RSV | RSV-F vaccine | Protein NPs | AEs; MAEs; SAEs; medically-attended LRTI | Novavax | Phase2 | NCT02247726 | ||
| RSV | RSV-F vaccine with adjuvant | Protein NPs | RSV LRTI or tachypnea 90 days | Novavax | Phase3 | NCT02624947 | ||
| RSV | RSV-F Vaccine | Protein NPs | Serum IgG antibody titers; GMEU; GMR; GMFR; SRR | Phase2 | Novavax | NCT01960686 | 214 | |
| EBV; Mononucleosis | EBV gp350-Ferritin Vaccine | Ferritin vaccine | Local and systemic reactogenicity; SAEs; AEs | Phase1 | NIAID | NCT04645147 | 778–780 | |
| EBV; Mononucleosis; Herpesvirus | EBV gp350-Ferritin Vaccine | Ferritin vaccine | mean EBV neutralizing antibody | Phase1; Phase2 | NIAID | NCT05683834 | 778–780 | |
| EBOV GP Vaccine | Ebola | Protein NPs | AEs; SAEs; MAEs; SNMCs; GMT; GMR; SCR; SRR | Phase1 | Novavax | NCT02370589 | 781 | |
| Drug delivery | ||||||||
| COVID-19 | Methotrexate-LDE | Lipid NPs | Lung injuries | Phase1; Phase2 | Azidus Brasil | NCT04352465 | ||
| Coronavirus; COVID-19; Inflammation | Methotrexate-LDE | Lipid NPs | Duration of hospital stay | Phase1; Phase2 | University of Sao Paulo General Hospital | NCT04610567 | ||
| COVID-19; Corona Virus | GS-5734 | Inhaled lipid NPs | AEs | Phase1 | NeuroActiva, Inc. | NCT04480333 | ||
| COVID-19 | VESTA respirator | Chitosan NPs | Incidence of laboratory-confirmed COVID-19 | NA | University of Brasilia | NCT04490200 | ||
| COVID-19 | Intranasal ivermectin spray | Aqueous nanosuspensions | Progression of COVID-19 clinical picture | Phase2; Phase3 | South Valley University | NCT04716569 | 263 | |
| Covid19 | MSC-exosomes | Exosomes | AEs | Phase1; Phase2 | AVEM HealthCare | NCT04798716 | ||
| COVID-19 | MSC-exosomes | Exosomes | Cytokine profile; inflammatory biomarkers | NA | University of Ulm | NCT05191381 | ||
| COVID-19 | Hemopurifier | Exosomes | AEs | NA | Aethlon Medical Inc. | NCT04595903 | ||
| Long COVID-19 Syndrome | UCMSC-derived exosomes | Exosomes | Cough Evaluation Test | Early-Phase1 | Huazhong University of Science and Technology | NCT05808400 | ||
| COVID-19 | Stem cell Exosomes | Exosomes | Symptom remission time; serum inflammatory markers | Early-Phase1 | First Affiliated Hospital of Wenzhou Medical University | NCT05787288 | 782,783 | |
| Severe COVID-19 | MSCs-derived exosomes | Exosomes | AEs; SAEs; TTIC | Phase1 | Ruijin Hospital | NCT04276987 | 250 | |
| Corona Virus; Pneumonia | CSTC-Exo | Exosomes | AEs; SAEs; TTCR | Phase1 | TC Erciyes University | NCT04389385 | ||
| COVID-19；ARDS | EV-Pure&WJ-Pure | Exosomes | AEs | Phase1 | Vitti Labs; LLC | NCT05387278 | ||
| COVID-19 | EXO-CD24 | Exosomes | AEs | Phase1 | Tel-Aviv Sourasky Medical Center | NCT04747574 | ||
| Corona Virus; COVID-19; SARS; ARDS | Zofin | Exosomes | AEs | Phase1; Phase2 | Organicell Regenerative Medicine | NCT04384445 | ||
| COVID-19 | Zofin | Exosomes | SAEs | Phase1; Phase2 | Organicell Regenerative Medicine | NCT05228899 | ||
| COVID-19 | EXO 1 &EXO 2 inhalation | Exosomes | AEs | Phase1; Phase2 | State-Financed Health Facility；Samara Regional Medical Center Dinasty | NCT04491240 | ||
| COVID-19 | CAP-1002 | Exosomes | Incidence of All-Cause Mortality | Phase2 | Capricor Inc. | NCT04623671 | ||
| COVID-19 | CovenD24 | Exosomes | SAEs; respiratory rate and SpO2 saturation | Phase2 | Athens Medical Society | NCT04902183 | ||
| COVID-19 | EXO-CD24 | Exosomes | Safety efficacy respiratory failure rate; death rate; PRO | Phase2 | Eli Sprecher; MD | NCT04969172 | ||
| COVID-19; ARDS | ExoFlo | Exosomes | 60-day Mortality Rate | Phase2 | Direct Biologics; LLC | NCT04493242 | 784 | |
| COVID-19 | EXO 1&EXO 2 | Exosomes | AEs | Phase2 | Olga Tyumina | NCT04602442 | ||
| COVID-19 | MSC-Exosome | Exosomes | Time to clinical improvement | Phase2; Phase3 | Dermama Bioteknologi Laboratorium | NCT05216562 | ||
| Antibiotic Resistant Infection | CIP-CS-PLGA-NPs | Chitosan coated PLGA NPs | Controlled release | Early-Phase1 | British University In Egypt | NCT05442736 | ||
| Cryptococcal Infections | Encochleated Amphotericin B | Lipid-crystal NPs | Tolerability of drug over 14 days | Phase1; Phase2 | Matinas BioPharma Nanotechnologies, Inc. | NCT03196921 | ||
| Bacterial Infections Oral | Chitosan | Coated PLGA NPs | Bacterial count | NA | British University In Egypt | NCT05475444 | ||
| Carious Lesion | Titania nanoparticle reinforced bonding agent | Titania nanoparticle | Post-restorative sensitivity | NA | Pakistan Institute of Medical Sciences | NCT05744648 | ||
| Glutathione-cyclodextrin Complex Absorption | GSH-CD | GSH-CD | GSH | Phase1 | Western University of Health Sciences | NCT05926245 | 423 | |
| Sepsis | Circulating Exosomes | Exosomes | mortality; All-cause mortality,28 days | NA | University of Kansas Medical Center | NCT04979767 | ||
| Sepsis; Critical Illness | MSC-EXO | Exosomes | The death rate of children | NA | Children’s Hospital of Fudan University | NCT04850469 | ||
| Drug-resistant | haMPC-Exos | Exosomes | Clinical cure rate,8 days | Phase1; Phase2 | Ruijin Hospital | NCT04544215 | ||
| Tinea | Oxiconazole nitrate SLNs loaded gel | SLNs | Clinical improvement; AEs | Phase1 | Minia University | NCT03823040 | ||
| Drug | ||||||||
| COVID-19 | Mouthwash and nose rinse with the AgNPs | AgNPs | Incidence of SARS-CoV-2 infection | NA | Cluster de Bioeconomia de Baja California, A.C | NCT04894409 | ||
| HIV | TLC-ART | DCNP | Cmax; Tmax | Phase1 | University of Washington | NCT05850728 | ||
| HIV | DermaVir; HAART | HIV-like particles | HIV-specific memory T cells | NA | Genetic Immunity | NCT00918840 | ||
| HIV | DermaVir; | HIV-like particles | Primary safety endpoint | Phase2 | Genetic Immunity | NCT00711230 | ||
| HIV | DermaVir; HAART | HIV-like particles | Grade 3 Adverse Event | Phase1 | Genetic Immunity | NCT00712530 | ||
| HIV | RPV | Nanosuspensions of pure drug | Cmax; AUC (last) | Phase1 | Janssen Infectious Diseases BVBA | NCT02547870 | 785,786 | |
| HIV | RPV | Nanosuspensions of pure drug | AEs | Phase1 | Janssen Research & Development, LLC | NCT01656018 | 265 | |
| HIV | V3G CH848 Pr-NP1; 3M-052-AF | Ferritin NPs; LNP | AEs; SAEs; MAAEs; AESIs | Phase1 | NIAID | NCT05903339 | ||
| Candida Infection | Titanium dioxide NPs | Titanium dioxide NPs | Bacterial colony-forming units | NA | Cairo University | NCT03666195 | ||
| Nosocomial Infections | AgNPS; copper NPs | Mental NPs | The inhibition zone; antibiofilm Activity | NA | Sohag University | NCT04775238 | ||
| Caries Class Ii | Nano Care Gold | Gold & AgNPS | Marginal adaptation | Phase1 | Cairo University | NCT03669224 | ||
| Fungal Foot Infection | Whitfield; zinc oxide NPs | Zinc oxide NPs solution | KOH test | Phase4 | Mahidol University | NCT05901961 | ||
| Foot Infection Fungal | AgNPS | AgNPS | The antimicrobial activity | Phase1 | Ahmed A. H. Abdellatif | NCT03752424 | ||
| Cutaneous Leishmaniasis | Sm29 Protein | AuNPS | Cure, 90 days | Phase1; Phase2 | Hospital Universitário Professor Edgard Santos | NCT06000514 | ||
| Dietary supplement | Recurrent Urinary Tract Infection | Magnalife | Nanotechnology Structured water | Urinalysis by GUE | NA | University of Sulaimani | NCT04306731 | |
| Sensors | Tuberculosis | Nanodisk-MS assay | Silicon NPs | Correlation, Sensitivity, specificity, positive predictive value, and negative predictive value | NA | Chinese University of Hong Kong | NCT03271567 | 430 |
| Biomarker | Sepsis With MOD | NTA double markers | Fluorescent NPs | Ubiquitination-autophagy-apoptosis biomarkers | NA | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | NCT03222986 | |
| Sepsis complicated with ARDS | Diagnostic test | Exosomes | Differential miRNAs | NA | Tianjin Nankai Hospital | NCT05476029 | ||
| Sepsis | Antibiotics | Exosomes | Amount of dendritic cell-derived exosomes | NA | Jinling Hospital, China | NCT02957279 | ||
| Inflammatory diseases | ||||||||
| Drug delivery | Rheumatoid Arthritis | Nanoparticulated rebamipide | LNEs | Change in the Clinical improvement of oral ulcers | Phase3 | Cairo University | NCT04649697 | |
| Atherosclerosis; coronary artery disease; inflammation | Methotrexate-LDE | LDL Like NPs | LAPV coronary | Phase2; Phase3 | University of Sao Paulo General Hospital | NCT04616872 | ||
| Coronary artery aisease; atherosclerosis; inflammation | LDE-Paclitaxel | LDL Like NPs | LAPV coronary | Phase2; Phase3 | University of Sao Paulo General Hospital | NCT04148833 | ||
| Atherosclerosis | Iron-bearing NPs | Iron-bearing NPs | TAV; QCA; IVUS | NA | Ural State Medical University | NCT01270139 | ||
| Coronary artery disease; atherosclerosis | Iron-bearing NPs | Iron-bearing NPs | TAV; IVUS | Phase1 | Ural State Medical University | NCT01436123 | ||
| Painful diabetic neuropathy | 0.75% capsaicin nanoparticle cream | SLNs | Pain relief | Phase2; Phase3 | Mahidol University | NCT01125215 | ||
| PreDiabetes | Zein nanocapsules | Zein NPs | Change in Fructosamine | NA | Clinica Universidad de Navarra, Universidad de Navarra | NCT05560412 | ||
| Chronic diabetic foot ulcer | Stem cell product | Chitosan NPs | Complete healing, full epithelization of chronic diabetic foot ulcer, 6 months | Phase1 | Assiut University | NCT03259217 | ||
| Plaque Psoriasis | SOR007 Ointment | LNEs | Change in the thickness of the ELB, 12 days | Phase1 | DFB Soria, LLC | NCT03004339 | ||
| Dementia; alzheimer Disease | APH-1105 | LNEs | ADAS-Cog | Phase2 | Aphios | NCT03806478 | 787 | |
| Tubular breast cancer; inflammatory breast cancer | Nab-Paclitaxel (Abraxane®) | Protein-NPs | Pathological complete Response (pCR=ypT0 ypN0) rates | Phase3 | German Breast Group | NCT01583426 | ||
| Inflammatory breast cancer | Carboplatin; paclitaxel albumin-stabilized nanoparticle formulation | Protein-NPs | Pathological complete response (pCR=ypT0 ypN0) rates | Phase2 | City of Hope Medical Center | NCT01525966 | 788 | |
| Breast cancer | capecitabine; paclitaxel albumin-stabilized nanoparticle formulation; neoadjuvant therapy | Protein-NPs | Pathological complete response rate | Phase2; Phase3 | Medstar Health Research Institute | NCT00397761 | ||
| Breast cancer; HER2-negative breast cancer | Carboplatin; paclitaxel albumin-stabilized nanoparticle formulation | Protein-NPs | Progression free survival | Phase2 | University of California, Irvine | NCT00618657 | ||
| Irritable bowel disease | Ginger exosomes | Exosomes | Change in inflammation on Colonoscopy | NA | University of Louisville | NCT04879810 | ||
| Ankylosing Spondylitis | Nanocurcumin | Nanomicelles spherical water | BASDI | Phase2 | Tabriz University of Medical Sciences | NCT03140657 | ||
| Drug | Chronic rhinosinusitis | Colloidal AgNPS | AgNPS | SNOT-22 | Phase1 | Washington University School of Medicine | NCT03243201 | |
| Knee arthritis; rheumatoid arthritis | Gold factor | AuNPs | KOOS | NA | 4Life Research, LLC | NCT05347602 | ||
| Type 1 Diabetes | C19-A3 GNP | Peptide-AuNPS | General safety and induction of hypersensitivity | Phase1 | Cardiff University | NCT02837094 | ||
| Inflammatory disease | Inhaled AgNPS | AgNPS | Ex vivo inflammatory response | NA | NIEHS | NCT02408874 | ||
| Crohn’s Disease | Placenal MSC derived exosomes | Exosomes | Safety of injected exosomes | Phase1; Phase2 | Tehran University of Medical Sciences | NCT05499156 | ||
| Multiple Sclerosis | Gold nanocrystals | AuNPs | CNS metabolic changes | Phase2 | Clene Nanomedicine | NCT03993171 | ||
| Dietary supplement | Type2 diabetes | Magnalife | Nanotechnology structured water | HbA1c | NA | ALI KAMAL M. SAMI | NCT04082351 | |
| Sensors | ||||||||
| Multiple sclerosis | NA-NOSE artificial olfactory system | Carbon nanotubes and AuNPS | Identification of volatile compounds in exhaled breath | complete | Carmel Medical Center | NCT01465087 | ||
| Multiple sclerosis | NA-NOSE artificial olfactory system | Carbon nanotubes and AuNPS | Successful discrimination | NA | Carmel Medical Center | NCT01206023 | ||
| Metabolic syndrome; diabetes | Breath analysis and blood analysis | nano-chemical sensors | Development of diabetes or complication | Phase1 | Rambam Health Care Campus | NCT01268813 | ||
| Neurodegenerative diseases (AD, PD) | ™NA-NOSE | Carbon nanotubes and AuNPS | NA | NA | Rambam Health Care Campus | NCT01291550 | 594 | |
| Imaging marker of MRI | ||||||||
| Multiple sclerosis | USPIO nanoparticle | USPIO nanoparticle | Signal change on T1-weighted and 3D UTE MRI brain | Early-Phase1 | University of Utah | NCT05357833 | ||
| Multiple sclerosis | Ferumoxytol | Iron oxide NPs | Brain signal intensity | Phase1 | NINDS | NCT02511028 | ||
| Myocardial infarction; inflammation | Cardiac magnetic resonance imaging | Iron-bearing NPs | Cardiac MRI signal intensity | NA | University of Edinburgh | NCT01127113 | ||
| Diabetes mellitus, type 1 | Ferumoxtran-10 | Iron oxide NPs | Changes in the pancreas associated with autoimmune diabetes | NA | Joslin Diabetes Center | NCT00585936 | ||
| Biomarker | Pleomorphic adenoma of salivary glands | CD24-Gold Nanocomposite | AuNPS | Non-conjugated CD24 | NA | Amina Fouad Farag | NCT04907422 | 789 |
| Hemodynamic instability; autophagy | Hemodynamic parameters | Exosomes | Change of hemodynamic parameters | NA | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | NCT03267160 | ||
Data available as of 15 September 2023. Data obtained from https://clinicaltrials.gov/. The first column highlights nanoparticles’ roles in diagnosing and treating diseases, such as their applications as vaccines, delivery vehicles, drugs, sensors, and diagnostic markers while the fourth column lists the various types of NPs
COVID-19 Corona Virus Disease 2019, CSTC-Exo COVID-19 Specific T Cell derived exosomes, AEs adverse reaction, SAE severe adverse reaction, TTIC time to clinical improvement, LNP lipid nanoparticle, NA not applicable, TTCR time to clinical recovery, PRO patient-reported outcome measure score, rep RNA representations of RNA sequences, SF-36 the 36 item Short Form Health Survey, GMT geometric mean titer, GMTR geometric mean titer ratio, GMFR geometric mean fold rise, SRRs seroresponse rates, NI non-inferiorto, NIAID National Institute of Allergy and Infectious Diseases, PRNT plaque reduction neutralization test, AESIs adverse events of special interest, PIMMCs potentially immune-mediated medical conditions, MAAEs medically attended adverse events, NOCMCs new onset chronic medical conditions, GMEU geometric mean EU, RBD receptor-binding domain, GMR geometric mean ratio, SRR seroresponse rate, RSV Respiratory Syncytial Virus, qNIV quadrivalent hemagglutinin (HA) nanoparticle influenza vaccine, CIC vaccine in-clinic mix of various doses of qNIV, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant, ICC Vaccine qNIV and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant, SCR2 and SCR4 proportion of subjects with two 2- and 4-fold seroconversion rates, MedDRA Medical Dictionary for Regulatory Activities, NINDS National Institute of Neurological Disorders and Stroke, ALFQ army liposomal formulation QS21, AgNPs silver nanoparticles, pNT50 geometric mean neutralizing antibody titers against D614G pseudovirus strain, MN50 inhibitory concentration of 50%, LRTI medically-attended RSV lower respiratory tract infection, MSD Multiplex Meso Scale Discovery; ILI influenza like illnesses, EBV Epstein-Barr Virus, DLCD diffusing capacity of the lungs for carbon monoxide, CRF case report form, HAI-Ab hemagglutination inhibition HAI antibody Ab, PCR Polymerase Chain Reaction, NT50 the 50% neutralizing antibody titers, PBNA pseudovirusbased neutralization assay, IgG Immunoglobulin G, SARS CoV-2 spike RBD protein-specific binding antibody bAb IgG and SARS CoV-2-specific neutralizing antibody nAb, Cmax peak TLC-101 drug substance concentrations, AUC area under the plasma concentration, MSCs mesenchymal stem cells, UCMSCs umbilical cord mesenchymal stem cells, PLGA poly-lactic-co-glycolic acid, SNMC significant new medical condition, Tmax time to maximum TLC-101 concentration, NAAT nucleic acid amplification testing, MOD multiple organ dysfunction, NTA nanoparticle tracking analysis, ARDS Acute Respiratory Distress Syndrome, HIV Human Immunodeficiency Virus, RPV Rilpivirine, MTX-LDE lipid NPs carried methotrexate, DCNP drug combination nanoparticle, LNEs lipid nanoemulsions, ELB change in the thickness of the echolucent band, SNOT-22 Sino-Nasal Outcome Test, KOOS knee injury and osteoarthritis outcome score; LAPV low attenuation plaque volume coronary; LDL low-density lipoprotein; SLNs solid lipid nanoparticles, TAV total atheroma volume, QCA quantitative coronary angiography, CD24 cluster of differentiation 24, IVUS intravascular ultrasound, NA-NOSE nanoparticle nose ADAS-Cog, the Alzheimer’s Disease assessment scale-cognitive subscale test, ELB echolucent band, BASDI assessments of ankylosing spondylitis signs and symptoms, USPIO ultrasmall superparamagnetic iron oxide, GSH-CD glutathione–cyclodextrin nanoparticle complex